The renal urate transporter SLC17A1 locus: confirmation of association with gout.

INTRODUCTION: Two major gout-causing genes have been identified, the urate transport genes SLC2A9 and ABCG2. Variation within the SLC17A1 locus, which encodes sodium-dependent phosphate transporter 1, a renal transporter of uric acid, has also been associated with serum urate concentration. However, evidence for association with gout is equivocal. We investigated the association of the SLC17A1 locus with gout in New Zealand sample sets.
METHODS: Five variants (rs1165196, rs1183201, rs9358890, rs3799344, rs12664474) were genotyped across a New Zealand sample set totaling 971 cases and 1,742 controls. Cases were ascertained according to American Rheumatism Association criteria. Two population groups were studied: Caucasian and Polynesian.
RESULTS: At rs1183201 (SLC17A1), evidence for association with gout was observed in both the Caucasian (odds ratio (OR) = 0.67, P = 3.0 × 10-6) and Polynesian (OR = 0.74, P = 3.0 × 10-3) groups. Meta-analysis confirmed association of rs1183201 with gout at a genome-wide level of significance (OR = 0.70, P = 3.0 × 10-8). Haplotype analysis suggested the presence of a common protective haplotype.
CONCLUSION: We confirm the SLC17A1 locus as the third associated with gout at a genome-wide level of significance.

Introduction

Regulation of serum urate concentration is central to the development of gout, with renal uric acid excretion a critical checkpoint [1]. Genome-wide association scans examining the genetic control of serum urate concentrations have identified two renal urate transporters - SLC2A9 and ABCG2 - that have a strong effect on gout risk in multiple ethnic groups [2]. Whilst other loci (SLC22A11, GCKR, INHBC, SLC17A1, RREB1, PDZK1, SLC16A9, LRRC16A) have been associated with serum urate concentrations at a genome-wide level of significance in genome-wide association scans [3,4], only some of them (SLC22A11, GCKR, INHBC, SLC17A1) were associated with gout at a nominal level of significance (P < 0.05) in 1,100 cases nested within a large genome-wide association scan population-based cohort [4]. To understand why some loci do not associate with gout, and to assess the weakly associated loci in clinical gout, it will be necessary to minimize heterogeneity owing to the type of gout (primary or secondary to other causes such as diuretic use) and to test for association in clinically proven cases.

The solute carrier family 17 member 1 (encoded by SLC17A1), also known as sodium phosphate transport protein 1 (NPT1), is expressed on the apical membrane of renal tubular cells and mediates sodium and inorganic phosphate co-transport [5]. Sodium-dependent transporter 1 has also been identified as a urate transport protein [6,7], probably secretory [7] with the gout-protective allele of I269T [8] leading to increased sodium-dependent transporter 1 activity [6] and, presumably, increased secretion of uric acid. Genome-wide association scans have shown that genetic variants associate with serum urate concentration in a Caucasian sample [3,4]. SLC17A1 has been associated with gout in a Japanese sample set (I269T (rs1165196), odds ratio (OR) = 0.55, P = 0.005) [8] but with conflicting results in Caucasian sample sets. Marker rs1165205 in SLC17A3 was first associated with gout (OR = 0.85, P = 0.002) [9]. A later study incorporating the same clinical material with additional cases and controls, however, reported reduced combined evidence for association with gout using a strongly correlated marker within SLC17A1 (rs1165196, r2 = 0.96; OR = 0.89, P = 0.013) [4] - in this study the markers most strongly associated with serum urate were within SLC17A1 (rs1165196 and other tightly correlated markers), suggesting that this gene was more likely than SLC17A3 to harbor an etiological variant. A separate study reported no evidence in Caucasian for association with gout (rs1183201, r2 with rs1165196 = 0.87, OR = 0.97, P = 0.68) [10]. This equivocal evidence for association with gout in a Caucasian population is notable given the genome-wide evidence for association with serum urate concentration [4]. Both studies had adequate power to detect association of a moderate effect size, but neither study used clinical criteria to define gout.

Here, we aimed to test the SLC17A1 locus for association with gout, in multiple ancestral groups, using cases defined as a diagnosis of gout by the 1977 American College of Rheumatology (ARA) clinical criteria. The variants tested were rs1183201, demonstrated to influence serum urate concentration in Caucasian populations [3], the maximally gout-associated SNP (rs1165196 (I269T)) in Japanese [8], and three other SNPs predicted to tag major variation in Polynesian populations.

Materials and methods

Study participants

There were a total of four New Zealand (NZ) case-control sample sets, one of Caucasian ancestry and three of different Polynesian ancestries (see Supplemental Table S1 in Additional file 1). The sample sets were Eastern Polynesian (EP; NZ Māori and Cook Islands, 284 cases and 349 controls), Western Polynesian (WP; Samoa, Tonga, Niue and Tokelau, 251 cases and 144 controls), combined Eastern and Western Polynesian (EP/WP; 15 cases and 21 controls) and Caucasian (421 cases and 1,228 controls; of the controls, 590 had been SNP typed genome wide [11,12]). The EP samples were further subdivided into two groups to remove effects of stratification, as described in more detail below, based on the estimated proportion of EP ancestry (EP/N, 236 cases and 192 controls; and EP/Z, 48 cases and 157 controls). All gout cases recruited had a diagnosis of gout confirmed according to the ARA preliminary diagnostic criteria [13]. Controls self-reported as having no history of gout. Recruitment of cases was approved by the NZ Multi-Region Ethics Committee (MEC/05/10/130), and recruitment of controls by the Lower South Ethics Committee. All patients provided written informed consent for the collection of samples and subsequent analysis.

Analysis of genome-wide microsatellite data indicates a difference in population structure between Samoa and NZ Māori [14] - with a Māori sample set estimated to be ~85% Polynesian and ~15% Caucasian ancestry, and a Samoan sample set estimated at ~70% Polynesian, ~15% Asian and smaller components of Melanesian and Caucasian ancestry [14]. Analysis of genome-wide SNP data by principal component analysis also shows a difference in the first component between Samoan and Cook Island genomes [15]. Given data also showing heterogeneity in association of ABCG2 with gout in EP and WP sample sets [16], the analysis groups here were EP and WP. People of combined EP and WP ancestry were included as a separate group.

Power

The individual sample sets were inadequately powered to detect an effect size in gout equivalent to that reported previously (OR = 1.12) [4], with the largest dataset (Caucasian) estimated to have 29% power at α = 0.05. However, at larger effect sizes the Caucasian sample set was better powered (63% power at OR = 1.2, 90% power at OR = 1.3 and 99% power at OR = 1.4). The smaller individual Polynesian sample sets had less power (for OR = 1.4: EP = 67% and WP = 45% using a Han Chinese Beijing (CHB) estimate of minor allele frequency = 0.18), although the combined Polynesian sample set was adequately powered with 88% power at OR = 1.4.

SNP selection and determination of genotypes

Using CHB HapMap data as the most closely related and available population to Polynesia, Haploview software (Broad Institute, Cambridge, MA, USA) was used to define four haplotype blocks using the Gabriel confidence interval method covering SLC17A1 (defined by rs4712972 (25.772 Mb) to rs12192635 (25.881 Mb)). Variants tagging major haplotypes were selected: rs9358890 in block 1, rs3799344 in block 2, rs1183201 in block 3 (previously associated with control of serum urate concentration) [3] and rs12664474 in block 4. The haplotype blocks extended into flanking genes (SLC17A4 and SLC17A3). In Centre d'Etude du Polymorphisme Humain (CEU) Caucasian population and the CHB population, rs1183201 and rs3799344 exhibited some intermarker linkage disequilibrium (LD) (r2 = 0.77 and 0.50, respectively) and rs9358890 and rs12664474 also exhibited LD (r2 = 0.35 and 0.62, respectively). SNP rs9358890 is in SLC17A4, and rs12664474 is in SLC17A3. SNP rs1165196 (SLC17A1) was also selected, in strong LD with rs1183201 (r2 = 0.87 in CEU and 0.91 in CHB) (Figure 1).

Figure 1

Intermarker linkage disequilibrium for Caucasian and Chinese populations. Intermarker linkage disequilibrium r2 values for Caucasian (Centre d'Etude du Polymorphisme Humain; left) and Chinese (Han Chinese Beijing; right) populations. Approximate gene positions are shown. Diagram generated with Haploview using data from www.hapmap.org.

Genotyping was done by TaqMan® SNP genotyping assays (Applied Biosystems, Foster City, CA, USA) using a Lightcycler® 480 Real-Time PCR System (Roche, Indianapolis, IN, USA) for four SNPs: rs1183201 (assay ID: C_1911034_10), rs9358890 (assay ID: C_25595118_10), rs3799344 (assay ID: C_194536_10) and rs12664474 (assay ID: C_11189653_10). SNP rs1165196 was genotyped using Sequenom technology (Sequenom, Inc. San Diego, CA, USA). SNPs rs9358890 and rs12664474 had been genotyped over 590 of the Caucasian controls on the Affymetrix 6 SNP array (Affymetrix, Santa Clara, CA, USA) [12] - genotypes were imputed for rs3799344 and rs1183201with IMPUTE2, using HapMap3 CEU (NCBI Build 36 (db126b)) as reference haplotypes.

Statistical analysis

ORs were calculated using PLINK software [17]. Because the case-control sample sets were not matched for sex, association analysis also included sex as a possible confounder. Analysis of association of haplotypes was also performed using PLINK. Meta-analysis was carried out using Rmeta software (within STATA 8.0, Stata, College Station, TX, USA) to calculate the combined Mantel-Haenszel OR using a fixed-effects model and the Breslow-Day test for heterogeneity.

The Māori population of NZ is admixed, primarily Caucasian. This leads to genetic stratification, which is a confounding factor for case-control genetic studies, especially when the prevalence of disease differs between the interbreeding populations. The prevalence of gout in NZ Māori is approximately double that in NZ Caucasian [18]. Given this, it is not surprising that the EP case sample set, which is predominantly NZ Māori (78% of cases, 93% of controls), has a significantly greater proportion of self-reported EP grandparents than does the control sample set (average of 3.1 EP grandparents in cases vs. 2.5 in controls, P = 3.1 × 10-14 by t test). Sixty-seven biallelic genomic control markers (see Supplemental Table 2 in Additional file 1) were genotyped in the EP sample set, and STRUCTURE software [19] was used to estimate the individual proportion of EP ancestry. This estimation was performed using the following parameters: number of populations assumed to be two, 30,000 burn-in period, and 100,000 Markov chain Monte Carlo replications after burn-in. Caucasian control individuals genotyped for the 67 markers were included as representative of the ancestral Caucasian population to aid in population clustering, although we were unable to include EP ancestral representatives. Plots of self-reported ancestry versus STRUCTURE estimated ancestry are shown in Supplemental Figure 1 in Additional file 1. For association analysis we created two datasets matched for EP ancestry - EP/N with estimated EP ancestry > 0.65 (the geometric mean; 236 cases and 192 controls), and EP/Z with estimated EP ancestry ≤ 0.65 (48 cases and 157 controls). The estimated average proportion of EP ancestry in the EP/N sample set was 0.90 in cases and 0.88 in controls, and for the EP/Z group was 0.41 in cases and 0.40 in controls.

Table 2

Association of four-marker rs9358890-rs3799344-rs1183201-rs12664474 haplotypes with gout

	Frequency
Haplotypea	Case	Control	OR (95% CI)	P value
Caucasian
A-T-A-A	270 (0.339)	1044 (0.428)	0.66 (0.56 to 0.78)	1.5 × 10-6
A-C-T-A	327 (0.410)	876 (0.360)	1.22 (1.03 to 1.44)	0.014
A-C-T-G	121 (0.152)	284 (0.117)	1.34 (1.06 to 1.69)	0.015
G-C-T-G	47 (0.059)	104 (0.043)	1.39 (0.98 to 1.98)	0.067
EP/N
A-T-A-A	107 (0.239)	101 (0.274)	0.84 (0.61 to 1.15)	0.27
A-C-T-A	160 (0.356)	109 (0.297)	1.33 (0.99 to 1.78)	0.06
G-C-T-G	161 (0.360)	140 (0.380)	0.93 (0.70 to 1.23)	0.60
EP/Z
A-T-A-A	32 (0.372)	120 (0.414)	0.84 (0.51 to 1.38)	0.49
A-C-T-A	32 (0.372)	111 (0.384)	0.95 (0.58 to 1.56)	0.84
G-C-T-G	9 (0.105)	26 (0.090)	1.19 (0.53 to 2.64)	0.68
A-C-T-G	10 (0.116)	22 (0.075)	1.63 (0.74 to 3.59)	0.23
WP
A-C-T-A	171 (0.357)	96 (0.343)	1.07 (0.78 to 1.45)	0.70
A-T-A-A	116 (0.241)	89 (0.318)	0.68 (0.49 to 0.94)	0.021
G-C-T-G	171 (0.356)	77 (0.275)	1.46 (1.06 to 2.02)	0.021
A-C-T-G	12 (0.025)	12 (0.043)	0.57 (0.25 to 1.29)	0.17
EP/WP
A-T-A-A	5 (0.167)	16 (0.400)	0.30 (0.10 to 0.95)	0.035
A-C-T-A	15 (0.500)	13 (0.324)	2.08 (0.78 to 5.50)	0.14
G-C-T-G	6 (0.200)	11 (0.275)	0.66 (0.21 to 2.05)	0.47

CI, confidence interval; EP, Eastern Polynesian; OR, odds ratio; WP, Western Polynesian. aHaplotypes are listed in descending order of control frequency; those with frequency < 0.03 were excluded.

Results

Association with gout was observed in the NZ Caucasian sample set for rs1165196, rs1183201, rs3799344 and rs12664474 (OR = 0.71 (95% confidence interval (CI) = 0.60 to 0.83), P = 5.5 × 10-5; OR = 0.67 (95% CI = 0.57 to 0.79), P = 3.0 × 10-6; OR = 0.69 (95% CI = 0.58 to 0.81), P = 2.8 × 10-5; and OR = 1.36 (95% CI = 1.12 to 1.66), P = 1.3 × 10-3, respectively), but not for rs9358890 (OR = 1.31 (95% CI = 0.93 to 1.85), P = 0.17) (Table 1). Given the low LD between rs12664474 and rs1183201 in CEU (r2 = 0.16), suggesting the possibility of an independent effect at rs12664474, we tested for association of rs12664474 conditional on genotype at rs1183201 in the NZ Caucasian samples; there was no evidence for a separate genetic effect on gout risk at rs12664474 (P = 0.37). We also tested for conditional associations at rs1183201 and rs1165196 (r2 in controls = 0.90) - there was association at rs1183201 conditional on genotype at rs1165196 (P = 0.007), but not at rs1165196 when conditioned on genotype at rs1183201 (P = 0.14).

Table 1

Association analysis in New Zealand case-control sample sets

SNPa	Cases			MAF	Controls			MAF	P unadjusted	P adjusted b	OR (95% CI)	HWE case	HWE control
rs1165196	TT	CT	CC	C	TT	CT	CC	C
Caucasian	167 (0.400)	201 (0.482)	49 (0.118)	0.359	389 (0.318)	590 (0.482)	246 (0.200)	0.442	1.0 × 10-4	5.5 × 10-5	0.71 (0.60 to 0.83)	0.33	0.41
EP/N	130 (0.570)	86 (0.377)	12 (0.053)	0.241	98 (0.516)	77 (0.405)	15 (0.079)	0.282	0.19	0.26	0.81 (0.60 to 1.11)	0.65	0.98
EP/Z	16 (0.364)	22 (0.500)	6 (0.136)	0.386	53 (0.358)	64 (0.432)	31 (0.209)	0.426	0.51	0.88	0.85 (0.52 to 1.38)	0.72	0.16
WP	138 (0.556)	99 (0.399)	11 (0.044)	0.244	69 (0.496)	54 (0.388)	16 (0.115)	0.309	0.05	0.06	0.72 (0.52 to 1.00)	0.20	0.28
EP/WP	10 (0.667)	5 (0.333)	0 (0.000)	0.167	6 (0.316)	10 (0.526)	3 (0.158)	0.421	0.02	0.07	0.28 (0.09 to 0.87)	0.33	0.73
Combinedc									5.7 × 10-7		0.72 (0.64 to 0.82)
rs1183201d	TT	TA	AA	A	TT	TA	AA	A
Caucasian	158 (0.384)	205 (0.499)	48 (0.117)	0.366	356 (0.291)	608 (0.496)	261 (0.213)	0.461	2.0 × 10-6	3.0 × 10-6	0.67 (0.57 to 0.79)	0.13	0.89
EP/N	130 (0.570)	86 (0.377)	12 (0.053)	0.241	96 (0.505)	78 (0.411)	16 (0.084)	0.289	0.11	0.14	0.78 (0.57 to 1.06)	0.65	0.98
EP/Z	15 (0.349)	21 (0.488)	7 (0.163)	0.407	52 (0.349)	61 (0.409)	36 (0.242)	0.446	0.49	0.95	0.85 (0.52 to 1.39)	0.94	0.04
WP	132 (0.543)	101 (0.416)	10 (0.041)	0.249	68 (0.479)	57 (0.401)	17 (0.120)	0.320	0.03	0.03	0.70 (0.51 to 0.97)	0.08	0.35
EP/WP	9 (0.600)	6 (0.400)	0 (0.000)	0.200	7 (0.350)	10 (0.500)	3 (0.150)	0.400	0.07	0.11	0.38 (0.13 to 1.12)	0.25	0.99
Combinedc									3.0 × 10-8		0.70 (0.62 to 0.79)
rs9358890	AA	AG	GG	G	AA	AG	GG	G
Caucasian	366 (0.884)	47 (0.114)	1 (0.002)	0.059	1114 (0.912)	104 (0.085)	4 (0.003)	0.046	0.12	0.17	1.31 (0.93 to 1.85)	0.69	0.35
EP/N	97 (0.418)	99 (0.427)	36 (0.155)	0.369	80 (0.419)	78 (0.408)	33 (0.173)	0.377	0.80	0.71	0.96 (0.73 to 1.28)	0.21	0.07
EP/Z	34 (0.753)	11 (0.244)	0 (0.000)	0.122	129 (0.827)	26 (0.167)	1 (0.006)	0.090	0.44	0.42	1.41 (0.67 to 2.96)	0.35	0.80
WP	110 (0.440)	101 (0.404)	39 (0.156)	0.358	73 (0.507)	61 (0.424)	10 (0.069)	0.281	0.03	0.06	1.43 (1.04 to 1.95)	0.06	0.57
EP/WP	8 (0.533)	7 (0.467)	0 (0.000)	0.233	12 (0.571)	7 (0.333)	2 (0.095)	0.262	0.78	0.87	0.86 (0.29 to 2.55)	0.24	0.53
Combinedc									0.05		1.19 (1.00 to 1.41)
rs3799344	CC	CT	TT	T	CC	CT	TT	T
Caucasian	165 (0.404)	193 (0.473)	50 (0.123)	0.359	379 (0.309)	592 (0.483)	255 (0.207)	0.450	5.9 × 10-6	2.8 × 10-5	0.69 (0.58 to 0.81)	0.58	0.38
EP/N	128 (0.561)	88 (0.386)	12 (0.053)	0.246	97 (0.524)	73 (0.395)	15 (0.081)	0.278	0.46	0.37	0.84 (0.62 to 1.15)	0.53	0.80
EP/Z	17 (0.378)	22 (0.489)	6 (0.133)	0.378	53 (0.353)	64 (0.427)	33 (0.220)	0.433	0.35	0.72	0.79 (0.49 to 1.29)	0.79	0.49
WP	136 (0.551)	98 (0.397)	13 (0.053)	0.251	64 (0.457)	59 (0.421)	17 (0.121)	0.332	0.02	0.02	0.67 (0.49 to 0.93)	0.39	0.55
EP/WP	10 (0.667)	5 (0.333)	0 (0.000)	0.167	7 (0.350)	10 (0.500)	3 (0.150)	0.400	0.04	0.08	0.30 (0.10 to 0.95)	0.44	0.85
Combinedc									7.4 × 10-8		0.71 (0.62 to 0.80)
rs12664474	AA	AG	GG	G	AA	AG	GG	G
Caucasian	264 (0.632)	134 (0.321)	20 (0.048)	0.208	867 (0.707)	321 (0.262)	38 (0.031)	0.162	0.01	1.2 × 10-3	1.36 (1.12 to 1.66)	0.57	0.22
EP/N	90 (0.383)	104 (0.443)	41 (0.174)	0.396	74 (0.392)	77 (0.407)	38 (0.201)	0.405	0.79	0.17	0.96 (0.73 to 1.27)	0.25	0.03
EP/Z	25 (0.543)	18 (0.391)	3 (0.065)	0.261	107 (0.704)	39 (0.257)	6 (0.039)	0.168	0.05	0.13	1.75 (1.00 to 3.05)	0.92	0.32
WP	102 (0.411)	106 (0.427)	40 (0.161)	0.375	63 (0.444)	67 (0.472)	12 (0.085)	0.320	0.13	0.10	1.27 (0.93 to 1.73)	0.16	0.32
EP/WP	7 (0.467)	6 (0.400)	2 (0.133)	0.333	12 (0.571)	7 (0.333)	2 (0.095)	0.262	0.51	0.38	1.41 (0.51 to 3.92)	0.70	0.53
Combinedc									2.0 × 10-3		1.25 (1.09 to 1.43)

CI, confidence interval; HWE, {AU Query: Define}; MAF, {AU Query: Define}; OR, odds ratio. aGenotyping success rate: rs1165196 Caucasian, Eastern Polynesian (EP), Western Polynesian (WP) and EP/WP - cases 99.0%, 95.8%, 98.8% and 100%, respectively, controls 99.8%, 96.8%, 96.5% and 90.5%, respectively; rs1183201 Caucasian, EP, WP and EP/WP - cases 97.6%, 95.4%, 96.8% and 100%, respectively, controls 99.7%, 97.1%, 98.6% and 95.2%, respectively; rs9358890 Caucasian, EP, WP and EP/WP - cases 98.3%, 97.5%, 99.6% and 100%, respectively, controls 99.2%, 99.4%, 100% and 90.5%, respectively; rs3799344 Caucasian, EP, WP, EP/WP - cases 96.9%, 96.1%, 98.4% and 100%, respectively, controls 99.8%, 96.0%, 97.2% and 95.2%, respectively; rs12664474 Caucasian, EP, WP, EP/WP - cases 99.3%, 98.9%, 98.8% and 100%, respectively, controls 99.8%, 97.7%, 98.6% and 100%, respectively. bAdjusted for sex. cMeta-analysis by the Mantel-Haenszel method. Breslow-Day test for heterogeneity: rs1165196, P = 0.45; rs1183201, P = 0.75; rs9358890, P = 0.77; rs3799344, P = 0.58; rs12664474, P = 0.97. dPopulation attributable risk (the reduction in gout incidence if the risk variant was absent) for positivity of the risk (T) allele of rs1183201 is 38.2% for Caucasian, 21.4% for EP/N, 27.3% for EP/N and 41.3% for WP.

The five variants were then tested for association in the Polynesian sample sets (Table 1), with the only evidence for association in individual sample sets coming from WP at rs1183201 (OR = 0.70, P = 0.03) and rs3799344 (OR = 0.67, P = 0.02). However, meta-analysis of the Polynesian sample sets - carried out to increase power - replicated the association observed in Caucasian at rs1165196 (OR = 0.75 (95% CI = 0.60 to 0.94), P = 0.013, PHet = 0.33), rs1183201 (OR = 0.74 (95% CI = 0.61 to 0.91), P = 0.003, PHet = 0.57) and rs3799344 (OR = 0.74 (95% CI = 0.61 to 0.90), P = 0.003, PHet = 0.33), but not at rs9358890 (OR = 1.15 (95% CI = 0.95 to 1.40), P = 0.16, PHet = 0.28) or rs12664474 (OR = 1.16 (95% CI = 0.96 to 1.40), P = 0.13, PHet = 0.23).

The Caucasian and Polynesian sample sets were combined in meta-analysis for rs1165196 (OR = 0.72 (95% CI = 0.64 to 0.82), P = 5.7 × 10-7), rs1183201 (OR = 0.70 (95% CI = 0.62 to 0.79), P = 3.0 × 10-8, PHet = 0.64), rs9358890 (OR = 1.19 (95% CI = 1.00 to 1.41), P = 0.05, PHet = 0.37), rs3799344 (OR = 0.71 (95% CI = 0.62 to 0.80), P = 7.4 × 10-8, PHet = 0.43), and rs12664474 (OR = 1.25 (95% CI = 1.09 to 1.43), P = 2.0 × 10-3, PHet = 0.23). Of the five SNPs, rs1183201 was the only one significant at a genome-wide level of significance (P < 5 × 10-8). None of the SNPs were significantly associated with serum urate in either the Caucasian controls (for whom there were serum urate data available; see Supplemental Table 1 in Additional file 1) or the less admixed combined WP and EP/N controls (all P > 0.28).

Because haplotypes are multi-allelic we analyzed association of haplotypes with gout, with the purpose of investigating the mechanism of effect - that is, whether risk and/or protective variants are present and comparing association pattern between populations. Analysis of four-marker haplotypes (rs9358890-rs3799344-rs1183201-rs12664474; Table 2) revealed the most consistent evidence for association to come from the A-T-A-A haplotype (OR = 0.30 to 0.84), with significant association in the Caucasian, WP and EP/WP sample sets (P = 1.5 × 10-6 to 0.035).

Discussion

Genetic regulators of serum urate concentration that have been previously associated with gout at a genome-wide level of significance (P < 5 × 10-8) in Caucasian samples are SLC2A9 [4,9,20] and ABCG2 [4,9,16]. Here, we provide strong evidence for a role of the SLC17A1 locus in gout in a Caucasian population (rs1183201, OR = 0.67, P = 3.0 × 10-6; Table 1) that was replicated in Polynesian samples, with the minor allele of rs1183201 also conferring a similar degree of risk (OR = 0.74, Pmeta-analysis = 3.0 × 10-3). The haplotype data (Table 2) are consistent with the presence of at least one genetic variant influencing the risk of gout at the SLC17A1 locus. We hypothesize that the variant is protective of gout and is contained on a common haplotype (27 to 43%; A-T-A-A), conferring significant protection in three out of the five sample sets (also with OR < 1 in both EP sample sets). There were no haplotypes consistently conferring risk. Combining the populations provided a genome-wide level of significance for association of rs1183201 with gout (OR = 0.70, P = 3.0 × 10-8). This confirms the SLC17A1 locus as the third associated with gout.

The role of SLC17A1 has been previously evaluated in gout in a Japanese sample set [8], with the nonsynonymous variant I269T (rs1165196) having the strongest evidence for association (OR = 0.55, P = 0.004, minor allele (269T) protective). rs1165196 is in strong LD with rs1183201 -the maximally associated variant in our study - in Japanese (HapMap JPT) and Caucasian (HapMap CEU) samples (r2 = 0.92 and r2 = 0.87, respectively). Given that I269T has been shown to affect the function of SLC17A1, with the protective variant (269T, minor allele of rs1165196) leading to increased activity in Xenopus oocytes and, presumably, increased renal elimination of urate [6], it is therefore possible that rs1165196 is an etiological variant. However, we found no evidence in the Caucasian sample set supporting association at rs1165196 when conditioned on genotype at rs1183201, and association was weaker at rs1165196 than rs1183201 in combined Caucasian and Polynesian meta-analysis (OR = 0.72, P = 5.7 × 10-7 and OR = 0.70, P = 3 × 10-8, respectively) and in Polynesian alone (OR = 0.75, P = 0.013 and OR = 0.74, P = 0.003, respectively) (we did not conditionally analyze the small Polynesian sample sets). Ostensibly this observation argues that rs1183201 (or a variant in strong LD) is more likely than rs1165196 to be an etiological variant within SLC17A1. Given that rs1165196 has a stronger effect in serum urate levels in Caucasian ([4] β = 6.205 vs. 6.050 for rs1183201) populations, however, this interpretation should await further testing in larger gout and serum urate sample sets.

In the Caucasian analysis, rs1183201 was strongly associated with gout (OR = 0.67 (95% CI = 0.57 to 0.79)). This SNP, or SNPs in strong LD, has been studied for association with gout in two previous studies: Yang and colleagues [4], with OR = 0.89 (95% CI = 0.82 to 0.98); and Stark and colleagues [10], with OR = 0.97 (95% CI = 0.86 to 1.11). The strength of effect in our study is considerably greater than the previous studies, with a 95% CI that does not overlap with either study. Given that the control allele frequencies were similar between our study and those of Yang and colleagues [4] and Stark and colleagues [10] (0.461 (rs1183201), 0.46 (rs1165196), and 0.487 (rs1183201), respectively), the differences in effect size are therefore caused by differences in allele frequency in case sample sets. Differences in ascertainment of cases are a possible reason for this effect. Here, cases were clinically ascertained by ARA criteria with exclusion of patients suspected of having diuretic-induced gout. In Yang and colleagues' study, cases were drawn from five population-based cohorts and were ascertained by: self-report or allopurinol treatment (AGES Reykjavik Study); self-report (Atherosclerosis Risk in Communities Study); receiving gout medication (allopurinol, colchicine, probenecid; Cardiovascular Health Study); self-report (Framingham Heart Study); and receiving gout medication (allopurinol, colchicine, probenecid, benzbromarone; Rotterdam Study) [4]. In Stark and colleagues' study, cases were ascertained by self-report and review of medical history [10].

In the study by Yang and colleagues no details were included about the inclusion, or otherwise, of diuretic-induced cases [4]; and in the study by Stark and colleagues 36.1% of cases were taking diuretic medication [10]. The use of self-reported gout probably results in participants without clinical evidence for gout being included in case sample sets; for example, only 69% of men who self-reported as new cases of gout met the ARA classification criteria for gout [21], and reliability and sensitivity for self-reported gout have been estimated at 63 to 73% and 84%, respectively [22]. Although the reliability of use of medications such as allopurinol, colchicine, probenecid and benzbromarone has not been extensively investigated for gout classification, the use of allopurinol prescription gives a positive predictive value of 39% for probable/definite gout [23]. Certainly, gout case sample sets ascertained using such indirect criteria had lower effect sizes reported at SLC2A9, compared with sets using ARA criteria [20]. The method of ascertainment in the previous studies [4,10] would thus reduce power to detect association at SLC17A1 owing to inclusion of nongout participants in the case sample sets. The use of diuretic medications is well established as a gout risk factor [24], perhaps by inhibition of urate excretion mediated by human organic anion transporter 4 [25]. In Stark and colleagues' study [10], this could reduce power to detect association by studying cases with secondary gout, since the inhibitory effect of diuretic medication on organic anion transporter 4-mediated renal urate excretion would predominate over the genetic effect on gout risk mediated by the SLC17A1 locus. It is also conceivable that diuretics directly influence the function of urate transporters encoded in the locus. The loop diuretic bumetanide has recently been shown to be a transport substrate for sodium-dependent transporter 4 (encoded by SLC17A3), and functional polymorphic variants are likely to influence transport ability [26]. Given the likelihood that gene-diuretic interactions exist, one would be prudent to exclude gout cases taking diuretic medication as a potential confounding factor in order to evaluate the direct effect of genetic variation in the SLC17A1 locus on primary gout.

Conclusion

We provide, for the first time, a genome-wide level of evidence supporting a role for genetic variation in the SLC17A1 locus in the etiology of gout. This is the third urate transport locus associated with gout with this robust level of evidence, and our results further emphasize the importance of urate transport in gout.

Abbreviations

ABC: ATP-binding cassette; ARA: American Rheumatism Association; CEU: Centre d'Etude du Polymorphisme Humain; CHB: Han Chinese Beijing; CI: confidence interval; EP: Eastern Polynesian; LD: linkage disequilibrium; NZ: New Zealand; OR: odds ratio; SLC: solute carrier family; SNP: single nucleotide polymorphism; WP: Western Polynesian.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JEH-M, AJP-G and TRM helped to design the study, oversee its execution, and prepare the manuscript. GTJ, AvR, PJG, AAH, JH, PBJ, LKS and ND helped to provide clinical recruitment and prepare the manuscript. BC and GWM helped to collect data and prepare the manuscript. All authors read and approved the final manuscript.

Additional file 1

Supplemental Table 1 presenting participant demographic and clinical details, Supplemental Table 2 presenting genomic control SNPs, and Supplemental Figure 1 showing the correlation of self-reported number of EP grandparents with estimated EP ancestry using 67 genomic control markers.

Click here for file